As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Grace Therapeutics, Inc. The largest reported stake is Opaleye Management Inc.'s, at 13.07%. 10 filings are on record since August 14, 2025 (Schedule 13G, August 7, 2026).
Sell to companies like Grace Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 1,806,216 · Sole dispositive: 0 · Shared dispositive: 1,806,216 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 1,178,203 · Sole dispositive: 0 · Shared dispositive: 1,178,203 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Opaleye Management Inc. · Sole voting: 0 · Shared voting: 2,748,392 · Sole dispositive: 0 · Shared dispositive: 2,748,392 · SCHEDULE 13G, 2026-08-07
- · Holder: ADAR1 Capital Management, LLC · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Orin Hirschman · Percent: 4.9% · SCHEDULE 13G/A
Grace Therapeutics, Inc. has 10 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Opaleye Management Inc. | 13.07% | 2,748,392 | SCHEDULE 13G, 2026-08-07 | 2026-08-05 |
| ADAR1 Capital Management, LLC | 9.9% | 1,806,216 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Nantahala Capital Management, LLC | 6.75% | 1,178,203 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 4.9% | 814,000 | SCHEDULE 13G/A, 2026-04-27 | 2026-03-31 |
Holding shares or following this stake? See who's behind Grace Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Grace Therapeutics, Inc. and the records around it.
Grace Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
Watch Grace Therapeutics, Inc.
Get an email when Grace Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Grace Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Grace Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Grace Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 0 | 2,748,392 | 0 | 2,748,392 | SCHEDULE 13G, 2026-08-07 |
| Opaleye, L.P. | 0 | 2,748,392 | 0 | 2,748,392 | SCHEDULE 13G, 2026-08-07 |
| James Silverman | 0 | 2,748,392 | 0 | 2,748,392 | SCHEDULE 13G, 2026-08-07 |
| ADAR1 Capital Management, LLC | 0 | 1,806,216 | 0 | 1,806,216 | SCHEDULE 13G/A, 2026-08-14 |
| ADAR1 Capital Management GP, LLC | 0 | 1,525,757 | 0 | 1,525,757 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Schneeberger | 0 | 1,806,216 | 0 | 1,806,216 | SCHEDULE 13G/A, 2026-08-14 |
| Nantahala Capital Management, LLC | 0 | 1,178,203 | 0 | 1,178,203 | SCHEDULE 13G/A, 2026-08-14 |
| Wilmot B. Harkey | 0 | 1,178,203 | 0 | 1,178,203 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Mack | 0 | 1,178,203 | 0 | 1,178,203 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Grace Therapeutics, Inc. by CUSIP 00439U104 and gives its principal executive office as 103 Carnegie Center, Suite 300, Princeton, NJ 08540 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-01-28 | Orin Hirschman | 5.9% | SCHEDULE 13G/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-04-27 | Orin Hirschman | 4.9% | SCHEDULE 13G/A |
| 2026-05-15 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-08-07 | Opaleye Management Inc. | 13.07% | SCHEDULE 13G |
| 2026-08-14 | Nantahala Capital Management, LLC | 6.75% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
Questions about who owns Grace Therapeutics, Inc.
Who owns Grace Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Grace Therapeutics, Inc.: Opaleye Management Inc. (13.07%, Schedule 13G, filed 2026-08-07), ADAR1 Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-08-14) and Nantahala Capital Management, LLC (6.75%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Grace Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Grace Therapeutics, Inc. on this page are Opaleye Management Inc. (13.07%), ADAR1 Capital Management, LLC (9.9%) and Nantahala Capital Management, LLC (6.75%).
When did Opaleye Management Inc. buy into Grace Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Opaleye Management Inc. on this page is the Schedule 13G, filed 2026-08-07, reporting 13.07%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Grace Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 11, 2026 | Form D, private offering | $10M sold | Form D page | Source |
| June 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| February 25, 2025 | Form D, private offering | $15M sold | Form D page | Source |
Grace Therapeutics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Grace Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.